secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196475
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q2 Portfolio Receipts $608M (+12% YoY); raises FY 2024 guidance to $2.7-2.775B
--------------------------------------------------------------------------------

- Royalty Receipts grew 11% to $605M, driven by cystic fibrosis franchise, Trelegy (+32%), Tremfya (+34%), and Evrysdi (+91%).
- Raised FY 2024 Portfolio Receipts guidance: $2,700M-$2,775M (previous $2,600M-$2,700M), implying 9-12% Royalty Receipts growth.
- Capital deployed ~$2B YTD including $905M for Voranigo (approved Aug 6) and $575M expanded Cytokinetics collaboration.
- Issued $1.5B senior notes at 5.5% in June; total debt $7.8B at 3.1% avg cost; repurchased 4M shares for $115M YTD.
- Trodelvy Phase 3 TROPiCS-04 failed survival endpoint; BioCryst discontinued BCX10013 – potential portfolio headwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524196475/0001193125-24-196475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524196475/d857022d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer